TROP2 Membrane Localization Predicts Dato DXd Outcome

Company AstraZeneca; Daiichi Sankyo (Dato-DXd); academic investigators Event Type Peer-reviewed publication (Nature Medicine) Modality Computational pathology biomarker (TROP2 normalized membrane ratio) Asset Datopotamab deruxtecan (Dato-DXd) Target TROP2 Disease Area Nonsquamous NSCLC without actionable alterations Summary Source-gap reconciliation: a peer-reviewed Nature Medicine paper appeared online November…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *